Abstract 1904P
Background
Brain (BM) and bone metastases (BOM) in renal cell carcinoma (RCC) are associated with poor outcome. We evaluated real-world treatment paradigms of RCC patients with BM and BOM.
Methods
We retrospectively analyzed RCC patients with BM and BOM treated at 9 German tertiary cancer centres from 2003 to 2023. Adverse events (AE) were reported according to CTCAE 5.0, objective response rate (ORR) according to local standard. Progression free survival (PFS) and overall survival (OS) were calculated from start of treatment to progression or death.
Results
We included 349 patients with a median age of 64 years (IQR 55-71). 93% of all patients had BOM, 15% BM and 8% both. Most patients (86%) had clear cell RCC, 5% of all patients had sarcomatoid differentiation. 82% of patients had an ECOG PS of 0/1. IMDC risk was favorable/intermediate/poor in 19/58/23%. 76% received prior nephrectomy. Patients with BOM received first-line IO-combinations in 64% (IO-IO: 39%, TKI-IO: 61%), TKI-monotherapy in 36%, while patients with BM received IO-combinations in 73% (IO-IO: 42%, TKI-IO: 58%) and TKI in 27%. IO-based first-line therapy increased from 2003 to 2023. AE of all grades occurred in 87% and 50% during IO-based therapy or TKI monotherapy, and CTCAE grade ≥ 3 in 44% or 21%. ORR and survival outcomes with median follow-up of 33 months (IQR 14-78) are described in table. 49% and 50% of all patients with BOM and BM received second-line treatment, with Cabozantinib (34%; 31%) and Nivolumab (19%, 27%) being the most common treatment options.
Table: 1904P
Parameter | Total (%; n=270) | BOM (%; n=250) | BM (%; n=45) | ||||||
TKI n=95 | IO-IO n=69 | IO-TKI n=106 | TKI n=89 | IO-IO n=62 | IO-TKI n=99 | TKI n=12 | IO-IO n=19 | IO-TKI n=14 | |
ORR; % | 40 | 29 | 57 | 38 | 27 | 58 | 58 | 41 | 42 |
SD; % | 36 | 29 | 31 | 37 | 31 | 32 | 25 | 28 | 21 |
PD; % | 24 | 42 | 12 | 25 | 42 | 10 | 17 | 21 | 37 |
ORR vs. SD vs. PD | p<0.001 | p<0.001 | p=0.750 | ||||||
mPFS; months, 95% CI | 7 (5.2-8.8) | 7 (5.2-8.2) | 6 (3.1-8.9) | ||||||
mOS; months, 95% CI | 39 (29.5-48.5) | 39 (29.8-48.2) | 39 (19.1-58.9) |
Conclusions
RCC patients with BOM and BM are increasingly treated with IO-combinations but lead to higher rates of AE grade ≥ 3. In patients with BOM, IO-TKI revealed higher ORR compared to IO-IO combination, but not in patients with BM. Small sample size and retrospective design are major limitations of our analysis. Prospective studies evaluating treatment options for BOM and BM in patients with RCC is critical.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P. Paffenholz.
Funding
Has not received any funding.
Disclosure
P. Paffenholz: Financial Interests, Advisory Board: BMS, Janssen, Merck, Roche; Financial Interests, Invited Speaker: Apogepha, Astellas, BMS, Eisai, Ipsen, Janssen, Merck; Financial Interests, Funding: Astellas, AstraZeneca, Ipsen, Janssen, Medac, Merck. P. Ivanyi: Financial Interests, Coordinating PI: BMS, Bayer, Eisai, EMD Serono, Ipsen, Merck, Metaplan, MSD, Pfizer, Roche, Apogepha, AstraZeneca, Deciphera, Lilly, BB-Biontech. R. Wullenkord: Financial Interests, Advisory Board: Pfizer; Financial Interests, Funding: Astellas. S. Zschäbitz: Financial Interests, Advisory Board: Amgen, Bayer, BMS, Eisai, Janssen, MSD, Novartis, Pfizer; Financial Interests, Invited Speaker: Amgen, Bayer, BMS, Eisai, Janssen, MSD, Novartis, Pfizer; Financial Interests, Funding: Amgen, Astellas, AstraZeneca, Ipsen, Janssen, Merck, MSD, Pfizer. M. Schostak: Financial Interests, Personal, Advisory Board, and honoraria for speaking: AstraZeneca, BMS, Janssen, Merck, Sharp & Dome, Merck, Bayer Vital; Financial Interests, Personal, Advisory Board: Novartis, Roche; Financial Interests, Institutional, Local PI: AstraZeneca, Bayer Vital, BMS, Janssen, Merck, Ferring. K. Schlack: Financial Interests, Advisory Board: Apogepha, BMS, Eisai, EUSA Pharma, Ipsen, Merck, MSD, Novartis, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23